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Abstract 
Background: Community health workers (CHWs) were trained to identify children with malaria who could not take 
oral medication, treat them with rectal artesunate (RA) and refer them to the closest healthcare facility to complete 
management. However, many children with such symptoms did not seek CHWs’ care. The hypothesis was that the 
cost of referral to a health facility was a deterrent. The goal of this study was to compare the out-of-pocket costs and 
time to seek treatment for children who sought CHW care (and received RA) versus those who did not.
Methods: Children with symptoms of severe malaria receiving RA at CHWs and children with comparable disease 
symptoms who did not go to a CHW were identified and their parents were interviewed. Household out-of-pocket 
costs per illness episode and speed of treatment were evaluated and compared between RA-treated children vs. non-
RA treated children and by central nervous symptoms (CNS: repeated convulsions, altered consciousness or coma).
Results: Among children with CNS symptoms, costs of RA-treated children were similar to those of non-RA treated 
children ($5.83 vs. $4.65; p = 0.52), despite higher transport costs ($2.74 vs. $0.91; p < 0.0001). However, among chil-
dren without CNS symptoms, costs of RA-treated children were higher than the costs of non-RA treated children with 
similar symptoms ($5.62 vs. $2.59; p = 0.0001), and the main driver of the cost difference was transport. After illness 
onset, CNS children reached CHWs for RA an average of 9.0 h vs. 16.1 h for non-RA treated children reaching first treat-
ment [difference 7.1 h (95% CI − 1.8 to 16.1), p = 0.11]. For non-CNS patients the average time to CHW-delivered RA 
treatment was 12.2 h vs. 20.1 h for those reaching first treatment [difference 7.9 h (95% CI 0.2–15.6), p = 0.04]. More 
non-RA treated children developed CNS symptoms before arrival at the health centre but the difference was not 
statistically significant (6% vs. 4%; p = 0.58).
Conclusions: Community health worker-delivered RA does not affect the total out-of-pocket costs when used in 
children with CNS symptoms, but is associated with higher total out-of-pocket costs when used in children with less 
severe symptoms. RA-treated children sought treatment more quickly.
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Background
Children with severe disease deteriorate rapidly and die. 
Malaria deaths can be prevented by prompt treatment. 
Rectal artesunate (RA) is effective in preventing malaria 
deaths when given to children with danger signs (defined 
as inability to eat, drink or breastfeed, repeated vomiting, 
lethargy, convulsions, altered consciousness or coma) [1, 
2] together with a referral to the nearest hospital to com-
plete management [3].
The World Health Organization’s strategy for child sur-
vival, the Integrated Management of Childhood Illness 
(WHO-IMCI), focuses on the major childhood causes 
of mortality, including malaria [2, 4, 5]. In the commu-
nity component of this strategy (often referred to as inte-
grated community case management (iCCM) [6]), several 
interventions have been implemented to improve access 
to health care for children living in poor and remote areas 
[7]. In malaria endemic areas, under iCCM, community 
health workers (CHWs) are trained to recognize children 
with danger signs, to diagnose, and, if malaria positive, to 
treat with RA and refer the child to the closest healthcare 
facility for further management [5, 8].
Studies have investigated why children with uncompli-
cated fever, malaria or childhood illness in rural settings 
do not seek care at a CHW [9–14]. Often the symptoms 
were not perceived as severe and warranting CHW 
intervention [12, 14], drugs were out-of-stock [11–13], 
or parents had more confidence in the health centres 
and their drug supplies, personnel and training [11, 13, 
14]. Research examined fatal episodes and utilization of 
CHWs/modern biomedical care during severe fatal ill-
ness in Ethiopia, Uganda and Tanzania [15–17]. In the 
Ethiopian study [15], delays in seeking care were attrib-
uted to the waxing and waning of children’s symptoms 
which delayed seeking care, and inadequate knowledge 
about the need for early diagnosis and treatment whereas 
in the Tanzanian study the majority (78.7%) sought mod-
ern biomedical care, often from more than one provider; 
CHWs were not mentioned [17]. In both Uganda and 
Tanzania caregivers sought facility care [16, 17] with a 
minority using traditional care [17]. Other studies have 
reported that the majority of children who either die 
from severe illness or whose illness was recognized as 
being severe by the caregiver did not receive adequate 
treatment [18, 19], with one of the studies attributing this 
partially to the caregivers’ inability to pay for the costs 
of transport and treatment at a facility [19]. Household 
and health system costs of malaria episodes (uncom-
plicated or severe) have been estimated and modelled 
for 3 African countries showing that malaria household 
costs increase with disease severity and hospitalization 
[20]. Unfortunately, as pointed out in a 2003 review of 
the economic costs of malaria [21], direct information 
on household costs of severe malaria is lacking, partly 
because the condition is rare, making it difficult to obtain 
data through representative household surveys in a com-
munity, and because its symptoms (e.g. convulsions, loss 
of consciousness) may not lead to the condition being 
reported as malaria.
For children with severe illness, understanding the 
speed of treatment and referral is essential as delays in 
seeking care for severe malaria are associated with higher 
risk of death. Such a study also provides an important 
indicator of the quality of malaria interventions where 
the goal is to achieve malaria treatment within 24  h. 
However little is known about the speed of seeking treat-
ment at CHWs or compliance with referral advice. One 
study reported that 1/3 of children who were urgently 
referred by drug distributors experienced delays of more 
than 24 h [22].
Illness episodes impose costs on carers of sick children 
and these anticipated costs might influence their health-
seeking behaviour. While several studies have assessed 
the out-of-pocket costs of an episode of severe illness 
[23–26], there is no information on the out-of-pocket 
costs of households when RA is used and whether these 
costs might act as a deterrent. One study evaluated the 
cost-effectiveness of RA [27] and another assessed the 
out-of-pocket and societal costs for children who com-
pleted referral in an area where CHW-delivered RA was 
used [28]. A further study reported that children who 
received RA had poor adherence to referral to fee-based 
facilities [29]. The goal of this study was thus to evaluate 
household out-of-pocket costs for an episode of severe 
illness in children who received CHW-delivered RA 
compared to similar illness episodes in children who did 
not seek CHW’s care.
Methods
Study area and population
The study was undertaken in Burkina Faso and was 
nested within an intervention implementing malaria 
rapid diagnosis tests (RDTs) and oral and RA malaria 
treatment in malaria endemic villages via CHWs in the 
rural area of Sidéradougou, Mangodara District in 2015 
[30].
For this study, children who received CHW-delivered 
RA-treatment and children who did not were identified, 
and the out-of-pocket costs incurred by their families, 
clinical outcomes (i.e. deterioration to CNS symptoms by 
arrival at health centre) and the time from illness onset 
to treatment were compared. By definition, children who 
did not receive RA did not attend a CHW for diagnosis 
and treatment. Comparisons were made between chil-
dren with similar illness severity (such as repeated vom-
iting, lethargy, convulsions or altered consciousness/
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coma), but there was no attempt to sample similar num-
ber of children in different categories.
Guardians of children 6–59 months of age in the inter-
vention villages with a fever in the past 2  weeks were 
randomly selected for interview without knowledge of 
whether the children had uncomplicated or severe illness 
or sought CHW care [30]. Households without sick chil-
dren, whose caregiver was not present during the illness 
or refused consent were excluded from interview.
Children with similar symptoms to RA-treated chil-
dren, who did not seek CHW help, were identified from 
these random household sampling surveys and only ill-
ness episodes which had completed at the time when the 
parent or carer was questioned about out-of-pocket costs 
were included in the analysis. 1342 household interviews 
were conducted [30], but only 72 severe episodes con-
tributed to this analysis by meeting the eligibility crite-
ria of a completed illness episode in a child with danger 
signs warranting RA treatment, but where RA treatment 
was not sought (Fig.  1). Households were asked ques-
tions regarding the illness symptoms, treatment-seeking 
behaviour (healthcare providers visited, date and clock 
time visited, treatments provided) and the associated 
out-of-pocket costs.
Identical data on illness, treatment-seeking behav-
iour and costs was obtained from RA-treated children 
6–59 months, who were identified from the CHWs’ treat-
ment record forms. A total of 139 children received RA 
in Burkina Faso, 134 of whom were alive at the end of 
the episode (Fig. 1) [30]. At the time of study interviews 
(mid-2016), a further 11 children had died (and were 
excluded from the study as it was considered culturally 
insensitive to seek out-of-pocket cost data after a death); 
23 children had moved residence and were lost to follow 
up; and one child was inappropriately treated with RA. 
Thus, study data on a total of 99 RA-treated children with 
danger signs during illness episode was available.
Healthcare provision in the study area
In Burkina Faso, the “Centre de santé et de promotion 
sociale (CSPS)” is the first level of care for patients. CSPS 
are managed by nurses in outpatient facilities. Patients 
needing specialized care are referred to a “centre médi-
cal” (health centre) where admission and supervision by 
medical doctors is available; referral to the regional hos-
pital occurs if required. There is only one health centre 
in the study area. However, there are many traditional 
healers, CHWs, dispensaries/CSPS, and drug hawkers 
in addition to shops and pharmacies which sell quinine, 
2015: Burkina Faso: 29 villages
Use of rapid diagnosc tests and treatment: 
31 Community Health Workers (CHWs) provided with rectal artesunate 
139 with danger signs, treated with rectal 
artesunate, all went to hospital/health centre
603 went to a CHW
(excluded)
6,394 children treated  via a CHW
 (2015)
5 died
1,342 random household surveys of illness costs 
(2015)
134 alive
739 did not go to a CHW
Children traced for interviews 
on illness costs  
72 completed episodes
All included in analysis
105 children with danger signs
100 parents interviewed 
11 deaths & 23 children not found – excluded
1 child with no danger signs, wrongly treated - excluded
99 children included in analysis
Fig. 1 Identifying children with danger symptoms who received or not rectal artesunate
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antibiotics and anti-malarials (excluding the artemisinin 
derivatives) without prescription.
At the time of the study, health care provided at pub-
lic facilities was fee-based. The cost of consultation was 
about 200 West African CFA francs (XOF; US Dollars 
[USD] $0.33) and when admitted, the patient had to pay 
for their bed; no other costs were charged to the patient.
CHW training
As part of the intervention, CHWs were trained to diag-
nose malaria using RDTs at no cost to the patient, rec-
ognize severe illness (where children were unable to take 
oral medication and had “danger signs” requiring imme-
diate attention—inability to eat, drink or suck; repeated 
vomiting; lethargy; convulsions or altered consciousness/
coma) and treat malaria positive patients. For children 
with danger signs, free RA was provided, and all RA-
treated patients were referred to the closest healthcare 
facility for further management, with an explanation of 
the importance of reaching the facility quickly, to com-
plete patient management.
Community health worker training was in accordance 
with WHO Guidelines on IMCI which require that chil-
dren with fever or a history of fever within the previous 
24 h are assessed by a CHW. Training lasted 3 days and 
was evaluated through pre- and post-tests [31]. 31 CHWs 
passed certification for delivery of RA in 29 rural villages 
[30].
Questionnaires and data
Case report forms (CRFs) were developed in French and 
pilot tested before use. In CRFs, information was sought 
about the characteristics of the child and households 
(sex, age, education, occupation, household food scar-
city, the number of working people over 10  years old), 
the date and clock time from onset of each symptom, the 
date and clock time of visit (for each provider visited) and 
the out-of-pocket costs associated with each visit. Guard-
ians provided detail about the costs incurred at each 
healthcare provider for registration, consultation, diag-
nosis, drugs, bed, food/drinks and transport [14, 24–26]. 
All data were reported by the guardians from memory 
and the same interviewers were used for all household 
interviews to minimize interviewers’ bias. Identical 
information on illness, treatment-seeking behaviour and 
household costs was obtained for RA-treated and non-
RA treated patients. However, interviews for RA-treated 
patients did not occur within 2 weeks of the episode, but 
at the end of the intervention period.
Data analysis
For both RA and non-RA treated children, their ill-
ness symptoms were classified into cerebral symptoms 
involving the central nervous system (CNS—convulsions, 
coma or altered consciousness) and non-CNS symptoms 
(lethargy and/or repeated vomiting). Baseline character-
istics, the out-of-pocket costs and the duration of time 
from onset of symptoms to seeking treatment were com-
pared between RA and non-RA treated children catego-
rized by CNS status.
Out‑of‑pocket costs
Only direct out-of-pocket costs from onset of illness to 
recovery were collected and analysed. The opportunity 
cost of time taken by guardians to look after the child 
was beyond the scope of the study. In a sensitivity analy-
sis, the costs of non-RA treated patients who attended a 
health centre were also analysed. All data on costs were 
collected in XOF and were converted and presented in 
USD using the average exchange rate between April and 
October 2015: 1 USD = 598.09 XOF (http://www.oanda 
.com).
Time delays in seeking treatment
Because children with severe malaria deteriorate fast 
and die, time delays were calculated from clock times 
and dates provided by carers on the clinical course of ill-
ness and actions taken. From the clock times and dates 
reported by the main caregiver of the child, the duration 
of delay (in hours) was calculated: from onset of illness 
to arrival at 1st modern healthcare provider outside the 
home (CHWs, drug shops, dispensaries, health centres) 
and from onset of illness (and onset of danger signs) to 
arrival at the health centre. The time from administration 
of RA to arrival at health centre was calculated.
Deterioration
For both groups, deterioration was defined as the onset 
of CNS symptoms [32] prior to arrival at the health cen-
tre after a visit to a healthcare provider. For children in 
the RA-treatment group, this provider was the CHW.
Statistical methods
Data were double entered in EpiData 3.1 and analysed 
using Stata software, version 13.0 (StataCorp, College 
Station, Texas). A Student t-test was performed on the 
equality of means and a test of proportion on the equality 
of proportion with a level of significance of p = 0.05 and a 
confidence level of 95%, and either a test for heterogene-
ity or a linear trend of odds (if there were more than two 
ordered groups) was used to compare baseline character-
istics of those who received RA vs. those who did not, by 
CNS status.
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Results
Baseline characteristics
Table 1 presents the baseline characteristics of the chil-
dren, caregivers and illness episodes for RA-treated chil-
dren and non-RA treated children by CNS status. Most 
children in both RA and non-RA groups were less than 
36  months of age (86.9% RA; 59.7% non-RA). More 
than 75% of the guardians had no education and for 
the remaining, although not statistically significant, the 
guardians of RA-treated children were more educated 
than the guardians of non-RA treated children (e.g.: 2.0% 
RA vs. 0.0% non-RA treated guardians reported hav-
ing > 7 years of education).
Most households’ income was derived from agriculture 
(99.0% RA; 56.9% non-RA) but in 38.9% of the house-
holds of non-RA treated children, income was based on 
self-employment. RA-treated children went to a larger 
number of “modern” providers (> 1 provider: 100.0% RA 
vs. 1.4% non-RA), lived in households with higher num-
ber of working people (> 5 working people: 17.1% RA vs. 
2.8% non-RA), but lacked more food than non-RA fami-
lies (household food scarcity: often or always: 24.2% RA 
vs. 0.0% non-RA). Finally, most of the guardians (in both 
groups) spent less than 5  days in caring for their sick 
child (85.9% RA; 95.8% non-RA).
Household out‑of‑pocket costs for illness episode
All RA-treated patients incurred some costs during the 
illness episode (see Additional file  1). In the non-RA 
treated group, 83% of the patients with CNS and 77% 
without CNS incurred some costs, but in the case of non-
RA treated children who went to a health centre, they all 
incurred costs mainly because they paid for transport to 
the facility (87%), and the remaining 13% who did not 
incur transport costs paid for medications.
Table  2 presents the household costs by cost cate-
gory, for those who sought CHW care and were treated 
with RA and those who did not, by CNS status. Among 
patients who were not treated with RA, costs are pre-
sented also separately for those who went to a health 
centre. All patients treated with RA delivered by a CHW 
were referred to the health centre and all of them com-
pleted subsequent referral.
Total costs
For CNS patients, total costs were similar for RA-treated 
and non-RA treated patients, regardless of whether the 
latter went to a health centre ($5.83 vs. $4.65 p = 0.52) 
(Table  2). For non-CNS patients, RA-treated children 
incurred significantly higher total costs than non-RA 
treated children and the main driver of the cost differ-
ence was transport to a health centre and/or to a CHW: 
Total costs for non-CNS children: $5.62 for RA-treated 
vs. $2.59 for non-RA treated [difference $3.03 (95% CI 
1.51–4.54), p = 0.0001]. For patients who went to a facil-
ity, there was no significant difference in costs between 
RA-treated and non-RA treated patients.
Transport costs
Children treated with RA had significantly higher mean 
transport costs than children who were not because all 
RA-treated children completed referral at the health cen-
tre (Table  2). Transport was between 3 and 4.25 times 
higher for the RA group compared with all patients in the 
non-RA group, but only 1.7 times higher compared with 
the non-RA children who went to a facility. For CNS chil-
dren the average transport cost was $2.74 for RA-treated 
patients vs. $0.91 for non-RA treated patients [difference 
$1.83 (95% CI 1.25–2.42); p < 0.0001] and for non-CNS 
children, the transport cost was $2.38 for RA-treated 
patients vs. $0.56 for non-RA treated patients [difference 
$1.82 (95% CI 1.48–2.16), p < 0.0001]. For CNS patients 
who went to a facility the transport cost difference was 
just over one US dollar between the 2 groups: $2.74 for 
RA-treated patients vs. $1.57 for non-RA treated patients 
[difference $1.17 (95% CI 0.42–1.91), p = 0.0031]. For 
non-CNS patients who went to a facility the difference 
was similar: $2.38 vs. $1.31 or $1.07 difference [(95% CI 
0.59–1.54), p < 0.0001].
Drug costs
It is important to note that non-RA treated patients 
who went to the single referral health centre in the Dis-
trict had higher mean drug costs at the facility than RA 
patients (Table  2). In general, drug costs at the facil-
ity constituted around 66% of the total episode costs for 
non-RA patients and 22% for the RA group. For CNS 
patients who went to a health centre the drug cost dif-
ference was $3.91: $1.02 vs. $4.93 [(95% CI 1.36–6.47), 
p = 0.0036]. For non-CNS patients the difference was 
lower, but still significant $2.69: $1.35 vs. $4.04 [(95% CI 
1.04–4.36), p = 0.0017].
Other costs
For the other categories (registration, consultation, diag-
nosis, bed), costs were minor for both the RA and non-
RA groups while food costs were in general nine times 
higher for the RA group vs. the non-RA group: $1.74 vs. 
$0.19 [difference $1.55 (95% CI 1.01–2.09), p < 0.0001] 
(Table 2).
Speed of treatment
Table  3 reports the time taken in hours to seek treat-
ment for those who were treated with RA vs. those who 
were not, by CNS status. Almost half of the non-RA 
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Table 1 Baseline characteristics, by symptoms: children treated with RA versus children not treated with RA
Category CNS + other  symptomsa No CNS but prostrated 
with other  symptomsa
Total
RA No RA RA No RA RA No RA
N % N % N % N % N % N %
Total no. of children 30 – 24 – 69 – 48 – 99 – 72 –
Child characteristics
 Child’s age, months
  < 36 mo 25* 83.3 13 54.2 61* 88.4 30 64.6 86* 86.9 43 59.7
  ≥ 36 mo 5* 16.7 11 45.8 8* 11.6 18 35.4 13* 13.1 29 40.3
 Child’s gender
  Male 14 46.7 13 54.2 32 46.4 27 56.3 46 46.5 40 55.6
  Female 16 53.3 11 45.8 37 53.6 20 41.7 53 53.5 31 43.1
  Missing – – – – – – 1 2.1 – – 1 1.4
Caregiver and household characteristics
 Caregiver’s gender
  Male 3 10.0 – – 24* 34.8 – – 27* 27.3 – –
  Female 27 90.0 24 100.0 45* 65.2 48 100.0 72* 72.7 72 100.0
 Caregiver’s age, years
  15–24 1* 3.3 6 25.0 11* 15.9 16 33.3 12* 12.1 22 30.6
  25–35 15* 50.0 14 58.4 37* 53.6 26 54.2 52* 52.5 40 55.6
  36–50 11* 36.7 2 8.3 19* 27.6 3 6.2 30* 30.3 5 6.9
  > 50 – – – – 2* 2.9 – – 2* 2.0 – –
  Missing/unknown 3 10.0 2 8.3 – – 3 6.2 3 3.0 5 6.9
 Education
  No education 23 76.7 23 95.8 56 81.2 40 83.3 79 79.8 63 87.5
  ≤ 7 years 7 23.3 1 4.2 9 13.0 8 16.7 16 16.2 9 12.5
  > 7 years – – – – 2 2.9 – – 2 2.0 – –
  Missing/unknown – – – – 2 2.9 – – 2 2.0 – –
 Occupation
  Unemployed – – – – – – 3 6.2 – – 3 4.2
  Agriculture 30* 100.0 16 66.7 68* 98.6 25 52.1 98* 99.0 41 56.9
  Self-employed (only or + agriculture) – – 8 33.3 – – 20 41.7 – – 28 38.9
  Missing/unknown – – – – 1* 1.4 – – 1* 1.0 – –
 Household food scarcity
  Never 22 73.3 18 75.0 48* 69.6 32 66.7 70* 70.7 50 69.5
  Seldom – – 4 16.7 – – 10 20.8 – – 14 19.4
  Sometimes 1 3.3 2 8.3 1* 1.4 6 12.5 2* 2.0 8 11.1
  Often – – – – 2* 2.9 – – 2* 2.0 – –
  Always 6 20.0 – – 16* 23.2 – – 22* 22.2 – –
  Missing/unknown 1 3.3 – – 2* 2.9 – – 3 3.0 – –
 No. of working people over 10 years of age in the household
  ≤ 2 10 33.3 13 54.2 20* 29.0 24 50.0 30* 30.3 37 51.4
  3–5 13 43.3 10 41.7 35* 50.7 23 47.9 48* 48.5 33 45.8
  6–10 5 16.7 1 4.1 9* 13.0 1 2.1 14* 14.1 2 2.8
  > 10 1 3.3 – – 2* 2.9 – – 3* 3.0 – –
  Missing/unknown 1 3.3 – – 3* 4.4 – – 4 4.0 – –
Illness characteristics
 Providers  visitedb
  Traditional medicine only – – 3c 12.5 – – 10c 20.8 – – 13c 18.1
  Itinerant drug sellers/home stock only – – 7 29.2 – – 17 35.4 – – 24 33.3
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treated children went to a “modern” healthcare provider 
and were taken there within 24  h. However, comparing 
the mean time to obtain treatment from illness onset it 
is clear that RA-treated patients sought treatment sub-
stantially faster, usually in less than half the time of those 
not treated with RA. For CNS RA-treated children, the 
average time to RA treatment was 9.0  h vs. 16.1  h for 
those treated with other medications [time difference 
7.1 h (95% CI − 1.8 to 16.1), p = 0.11] and for non-CNS 
patients, the average time was 12.2 h for RA-treated chil-
dren vs. 20.1 h for non-RA treated children [time differ-
ence 7.9  h (95% CI 0.2–15.6), p = 0.04]. For RA-treated 
children, the average referral time to reach the health 
centre after RA was 3.2 h.
In general, although not significant in this study, non-
RA treated patients took more time to reach a health 
centre after onset of illness: 15.0  h vs. 19.1  h [time dif-
ference 4.1 h (95% CI − 2.0–10.2), p = 0.18], and a higher 
through not statistically significant different percentage 
of them deteriorated to one or more CNS symptoms by 
arrival (6% vs. 4%; p = 0.58).
Discussion
This study examines the out-of-pocket costs and time 
to seek treatment for children with severe febrile illness. 
Children treated with CHW-delivered RA were com-
pared with children who were not treated with RA in 
categories by cerebral malaria (CNS) status. Parents of 
children with CNS symptoms of repeated convulsions, 
altered consciousness or coma, treated with RA did not 
pay more than non-RA treated children. There was a 
trend for RA-treated children with CNS to reach the only 
healthcare facility more quickly, and consequently higher 
transport was their main expenditure. Despite higher 
transport costs, they had equivalent total costs to the 
CNS non-RA group, primarily because the latter spent 
significantly more on drugs. The higher costs may have 
been attributable to clinical deterioration, but this could 
not be confirmed.
The lack of a difference in out-of-pocket costs for RA-
treated and not treated children with CNS symptoms is 
an important finding. Firstly, children with CNS symp-
toms are at very high risk of death [33, 34]. Secondly, 
the requirement to proceed to hospital/health centre 
after treatment is essential, but often perceived to be a 
major cost deterrent to compliance with referral advice, 
thus potentially delaying assessment and definitive treat-
ment at the referral facility [35, 36]. In this study, trained 
CHWs explained the importance of referral and empha-
sized the need for rapid compliance with referral advice. 
Their consistent advice was heeded, even though par-
ents probably spent more for transport in order to arrive 
rapidly at the referral facility [37] as emergency transfer 
usually costs more than non-emergency transport [38]. 
Among patients with CNS symptoms, the transport 
and food costs of RA-treated children were three times 
higher than those of non-RA treated patients. However, 
parents of non-RA treated children arrived around 3  h 
Table 1 (continued)
Category CNS + other  symptomsa No CNS but prostrated 
with other  symptomsa
Total
RA No RA RA No RA RA No RA
N % N % N % N % N % N %
  Traditional medicine and home stock – – 1 4.2 – – – – – – 1 1.4
  1 “modern”  providerd – – 12 50.0 – – 20 41.7 – – 32 44.5
  2 “modern”  providersd 29 96.7 1 4.2 69 100.0 – – 98 99.0 1 1.4
  3 “modern”  providersd 1 3.3 – – – – – – 1 1.0 – –
 No. days lost caring for sick children: completed episode
  ≤ 2 d 12 40.0 8 33.3 8* 11.6 20 41.7 20* 20.2 28 38.9
  > 2–5 d 14 46.7 15 62.5 51* 73.9 26 54.2 65* 65.7 41 56.9
  > 5–8 d 4 13.3 1 4.2 9* 13.0 2 4.1 13* 13.1 3 4.2
  > 8 d – – – – 1* 1.5 – – 1* 1.0 – –
RA rectal artesunate, CNS central nervous system (convulsions; altered consciousness/coma), mo months, d days
* Test of heterogeneity: RA vs. no RA: p < 0.05
a Repeated vomiting ± too weak to take oral medication/“lethargy”
b 1 child without CNS did not go to any provider
c CNS: 1 child went to a traditional healer and 2 used local herbs at home; No CNS: 2 children went to a traditional healer, 8 used local herbs at home; Total: 3 children 
went to a traditional healer; 10 used local herbs at home
d “Modern” defined to include community health workers, drug shops, dispensaries, health centres, and hospitals for RA children and drug shops, dispensaries, and 
health centres for non-RA children. Traditional or informal care providers could have been used before modern providers
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later at the health centre, and paid almost five times more 
on drugs at the health centre than parents of RA-treated 
patients.
In contrast, although not significant in this study, 
children with CNS symptoms who did not seek CHW-
delivered RA but eventually went to a health centre not 
only took a longer time from the first symptom to con-
sult a “modern” provider (9.0 h vs. 16.1 h) but also 1.19 
times longer than RA-treated children with CNS symp-
toms to reach a health centre (14.5 h vs. 17.2 h). A higher, 
not statistically significant, proportion of children (6%) 
not treated with RA deteriorated to CNS symptoms by 
arrival at the health centre compared to RA-treated 
patients (4%). Since children were seen at the same health 
centre, it is possible that the clinical deterioration of the 
non-RA treated patients contributed to their higher drug 
expenditures at the centre compared with RA-treated 
children with CNS symptoms ($1.02 vs. $4.93).
The cost pattern and time delays for children without 
CNS symptoms (e.g. children with repeated vomiting/
lethargy but at lower risk of death [32, 33]) presented 
a different picture. Time delays from onset of illness to 
the first “modern” healthcare provider were signifi-
cantly longer (12.2 h vs. 20.1 h) and episode costs were 
significantly lower for non-RA treated children than for 
RA-treated children without CNS symptoms, probably 
because low-cost traditional treatments or home treat-
ments were used [39]. RA-treated children incurred 
twice higher costs, mainly because of transport costs 
to a facility. However, it was noted that non-RA treated 
patients spent substantially more on drugs at the health 
centre, possibly because of the deteriorating condition of 
the child at arrival.
The ideal is that all parents of children with danger 
signs recognize the gravity of the symptoms and pro-
ceed to a CHW or health centre as quickly as possible 
for diagnosis and treatment. However, these results are 
consistent with previous work suggesting that symptoms 
are dominant in decisions to proceed to hospital [23]. 
The results also confirm anthropological work [39], car-
ried out in Burkina Faso which suggests that treatment 
for symptoms corresponding with the biomedical pic-
ture of cerebral malaria and characterized by convulsions 
and coma (kono, a “bird-illness”) is the domain of gué-
risseurs (traditional health practitioners), used first, and 
often because traditional treatment is cheaper than the 
formal healthcare services; modern care occurs later. In 
contrast, the word sumaya linked to symptoms of fever, 
weakness, cold, loss of appetite, general body pain, diar-
rhoea, and vomiting is usually treated at home, by moth-
ers, with herbs or paracetamol. It is, therefore, possible 
that parents considered that repeated vomiting and leth-
argy could be self-managed and delayed consultation 
with a modern provider; the delay was apparent even for 
those who eventually went to a health centre.
Household costs for children who sought care at health 
centre are higher than reported in other countries. In 
Uganda, the mean total out-of-pocket costs of patients 
who completed referral, some of whom received RA, 
were $2.52 [28] vs. $5.68 in Burkina Faso although only 
the costs after referral were calculated in Uganda. Since 
the full costs of the episode were calculated in this study, 
these data are unique in providing direct total house-
hold costs for an episode of severe illness, excluding the 
opportunity cost of time, for patients treated with RA in 
their community.
The non-RA children who went to a health centre 
paid on average $6.56 ($8.09 if they had CNS symp-
toms and $5.72 if they had repeated vomiting/lethargy). 
Menon et al. [24] found similar results ($6.84) in Uganda 
and other studies reported similar out-of-pocket costs 
(Ghana: $6.40 for severe cases; Malawi: $5.30 for children 
under 5) [25, 26].
The analysis has been limited to financial costs incurred 
by patients who survived the episode until the interview. 
The opportunity cost of labour, either forfeited to look 
after a sick child or withdrawn from agriculture because 
of the episode, was not calculated. It was not possible 
to obtain costs of RA-treated patients who survived the 
episode but died before the interview date because this 
would have been culturally insensitive. RDT results were 
not available for children in the non-RA group, and many 
of these children may not have had malaria, whereas all 
children in the RA-treated group had RDT-confirmed 
malaria. A further limitation is that, although all cost and 
time data relied upon memory, the data for the non-RA 
treated patients was obtained within 2 weeks of the epi-
sode, whereas data for the RA-treated patients were col-
lected several months after the episode. It is difficult to 
determine whether costs in the RA-treated group were 
over or under-reported.
For several children in each group, the parents could 
not recall the exact date and/or time of symptoms/visits 
to a provider, and this resulted in incomplete informa-
tion on time-intervals for several patients. Deterioration 
to CNS symptoms between visiting the last treatment 
provider and arrival at the health centre was used as 
an exploratory analysis of the higher drugs costs of the 
non-RA group. Although it is possible that higher drug 
costs could have been due to clinical deterioration, this 
hypothesis could not be confirmed. Furthermore, there 
was no attempt to ask qualitative questions about the 
reasons for not going to the health centre, and, for those 
who went, on the difficulties/barriers encountered in 
reaching the facility. With hindsight, such qualitative 
data would have been informative. Finally, it should be 
Page 11 of 12Castellani et al. Malar J          (2018) 17:380 
mentioned that RDTs and RA costs are not included in 
out-of-pocket costs as these were provided free of charge.
Conclusions
This study reports evidence that children with CNS 
symptoms treated with RA incur similar household costs 
as children not treated with RA, despite the higher trans-
port costs incurred in following the referral advice. Chil-
dren without CNS symptoms treated with RA incurred 
higher total costs because of the costs of following refer-
ral advice. RA-treated children sought treatment more 
quickly, whether with or without CNS symptoms.
Additional file
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by symptoms: children treated with RA versus children not treated with 
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